EPC 001
Alternative Names: EPC-001Latest Information Update: 28 Nov 2024
At a glance
- Originator Elpis Biopharmaceuticals
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported B-cell lymphoma
Most Recent Events
- 28 Nov 2024 No recent reports of development identified for preclinical development in B-cell lymphoma in USA (Parenteral)
- 11 Apr 2022 Pharmacodynamics data from a preclinical study in B-cell lymphoma presented at the annual meeting of the American Association for Cancer Research (AACR-2022)
- 08 Apr 2022 Pharmacodynamics data from a preclinical study in B-cell lymphoma presented at the annual meeting of the American Association for Cancer Research (AACR-2022)